Therapeutic Insights into Braftovi (Encorafenib) + Erbitux (Cetuximab) ± Mektovi (Binimetinib) Combination Therapy
Overview of the Braftovi + Erbitux ± Mektovi Combination The combination therapy of Braftovi (encorafenib), Erbitux (cetuximab), and optionally Mektovi (binimetinib) has become a key treatment approach for certain cancers, particularly metastatic colorectal cancer (mCRC) with the BRAFV600E mutation. This targeted therapy utilizes the inhibition